336 related articles for article (PubMed ID: 19125549)
1. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
Linton A; Bacon T; Peterson M
J Manag Care Pharm; 2009; 15(1):42-54. PubMed ID: 19125549
[TBL] [Abstract][Full Text] [Related]
2. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
Johnson JT; Neill KK; Davis DA
J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with choice of pharmacy setting among DoD health care beneficiaries aged 65 years or older.
Linton A; Garber M; Fagan NK; Peterson M
J Manag Care Pharm; 2007 Oct; 13(8):677-86. PubMed ID: 17970605
[TBL] [Abstract][Full Text] [Related]
4. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
[TBL] [Abstract][Full Text] [Related]
5. Analysis of nonformulary use of PPIs and excess drug cost in a Veterans Affairs population.
Ajumobi AB; Vuong R; Ahaneku H
J Manag Care Pharm; 2012; 18(1):63-7. PubMed ID: 22235956
[TBL] [Abstract][Full Text] [Related]
6. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
[TBL] [Abstract][Full Text] [Related]
7. Formulary management in the Department of Defense.
Trice S; Devine J; Mistry H; Moore E; Linton A
J Manag Care Pharm; 2009 Mar; 15(2):133-46. PubMed ID: 19236127
[TBL] [Abstract][Full Text] [Related]
8. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan.
Harris BN; West DS; Johnson J; Hong SH; Stowe CD
J Manag Care Pharm; 2004; 10(5):449-55. PubMed ID: 15369428
[TBL] [Abstract][Full Text] [Related]
9. Esomeprazole formulary exclusion: impact on total health care services use and costs.
Alemayehu B; Ke X; Youssef NN; Crawley JA; Levine DS
Postgrad Med; 2012 May; 124(3):149-63. PubMed ID: 22691909
[TBL] [Abstract][Full Text] [Related]
10. Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
Jonasson C; Tvete IF; Hatlebakk JG
Scand J Gastroenterol; 2013 Sep; 48(9):1010-7. PubMed ID: 23859491
[TBL] [Abstract][Full Text] [Related]
11. The effect of a three-tier formulary on antidepressant utilization and expenditures.
Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
[TBL] [Abstract][Full Text] [Related]
12. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
Klepser DG; Huether JR; Handke LJ; Williams CE
J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
[TBL] [Abstract][Full Text] [Related]
13. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
Lucas LM; Gerrity MS; Anderson T
Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of proton pump inhibitors anti-ulcer drugs use in the Araba district primary care area].
Martínez Gorostiaga J; Echevarría Orella E; Calvo Hernáez B
Rev Esp Salud Publica; 2018 Aug; 92():. PubMed ID: 30100604
[TBL] [Abstract][Full Text] [Related]
15. Formulary management of proton pump inhibitors.
Byrne MF; Murray FE
Pharmacoeconomics; 1999 Sep; 16(3):225-46. PubMed ID: 10558037
[TBL] [Abstract][Full Text] [Related]
16. Effect of a therapeutic maximum allowable cost (MAC) program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada.
Mabasa VH; Ma J
J Manag Care Pharm; 2006 Jun; 12(5):371-6. PubMed ID: 16792443
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.
Pauly NJ; Brown JD
J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study.
Liu Y; Zhu X; Li R; Zhang J; Zhang F
BMJ Open; 2020 Nov; 10(11):e040473. PubMed ID: 33243802
[TBL] [Abstract][Full Text] [Related]
19. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions.
Khandelwal N; Duncan I; Rubinstein E; Ahmed T; Pegus C
J Manag Care Pharm; 2012 Apr; 18(3):247-55. PubMed ID: 22468733
[TBL] [Abstract][Full Text] [Related]
20. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.
Schneeweiss S; Maclure M; Dormuth CR; Glynn RJ; Canning C; Avorn J
Clin Pharmacol Ther; 2006 Apr; 79(4):379-88. PubMed ID: 16580906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
